Harbin Gloria Pharmaceuticals Co (SZSE:002437) Total Liabilities : ¥1,219 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Harbin Gloria Pharmaceuticals Co Total Liabilities?

Harbin Gloria Pharmaceuticals Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥1,219 Mil.

Harbin Gloria Pharmaceuticals Co's quarterly Total Liabilities declined from Sep. 2023 (¥1,701.23 Mil) to Dec. 2023 (¥1,442.22 Mil) and declined from Dec. 2023 (¥1,442.22 Mil) to Mar. 2024 (¥1,219.45 Mil).

Harbin Gloria Pharmaceuticals Co's annual Total Liabilities declined from Dec. 2021 (¥2,716.23 Mil) to Dec. 2022 (¥2,370.65 Mil) and declined from Dec. 2022 (¥2,370.65 Mil) to Dec. 2023 (¥1,442.22 Mil).

Harbin Gloria Pharmaceuticals Co Total Liabilities Historical Data

The historical data trend for Harbin Gloria Pharmaceuticals Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Gloria Pharmaceuticals Co Total Liabilities Chart

Harbin Gloria Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

4,819.08

2,594.31

2,716.23

2,370.65

1,442.22

Harbin Gloria Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2,235.15	1,891.57	1,701.23	1,442.22	1,219.45

Harbin Gloria Pharmaceuticals Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Harbin Gloria Pharmaceuticals Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1412.228	+	(0	+	29.991
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,442

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	3152.45	-	1710.231
	=	1,442

Harbin Gloria Pharmaceuticals Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1168.201	+	(19	+	32.252
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,219

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3079.865	-	1860.412
	=	1,219

Harbin Gloria Pharmaceuticals Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Harbin Gloria Pharmaceuticals Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Harbin Gloria Pharmaceuticals Co (SZSE:002437) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Gloria Pharmaceuticals Co Ltd (SZSE:002437) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

Beijing Road No 29, Harbin Economic and Technological Development Zone, Harbin, CHN, 150025

Website

http://www.gloria.cc

Harbin Gloria Pharmaceuticals Co Ltd is a tech biopharmaceutical enterprise. It is engaged in the research, development, production, and sale of pharmaceutical products primarily in China. The company offers cardiovascular drugs; cardiac cerebrovascular medication; vitamins and minerals; urinary tract drugs; urinary system medication; anti-tumor medication; endocrine system drugs; anti-infective drugs; digestive system medication; respiratory medication; and other medications.

Harbin Gloria Pharmaceuticals Co (SZSE:002437) Headlines

No Headlines